Clinical Trial: NCT06863233
A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer
Status:
COMPLETEDPhase:
Phase 1| Lead Sponsor: | Memorial Sloan Kettering Cancer Center |
| Information Provided By: | Memorial Sloan Kettering Cancer Center |
| Last Update Posted: | 2026-08-26 |
Study Overview
Brief Summary
The purpose of this study to learn whether PET/CT (positron emission tomography/computed tomography) scans using an imaging agent (radiotracer) called zirconium Zr 89 crefmirlimab berdoxam is a safe and effective way to identify CD8+ T cells
Official Title
Assessment of Patients Immune Response After Treatment With Engineered Tumor Infiltrating Lymphocyte Therapy Incorporating CD8 PET Imaging
Conditions
Lung Cancer, Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
Intervention / Treatment
- Drug: Zirconium Zr 89 crefmirlimab berdoxam
- Diagnostic Test: PET/CT Scan
Other Study ID Numbers
- 24-369
Start Date (Actual)
2025-03-03
Primary Completion Date (Actual)
2026-08-24
Study Completion Date (Actual)
2026-08-24
Enrollment (Actual)
4
Study Type
Interventional
Phase
Phase 1
| Lead Sponsor: | Memorial Sloan Kettering Cancer Center |
| Information Provided By: | Memorial Sloan Kettering Cancer Center |
| Last Update Posted: | 2026-08-26 |
Study Overview
Brief Summary
The purpose of this study to learn whether PET/CT (positron emission tomography/computed tomography) scans using an imaging agent (radiotracer) called zirconium Zr 89 crefmirlimab berdoxam is a safe and effective way to identify CD8+ T cells
Official Title
Assessment of Patients Immune Response After Treatment With Engineered Tumor Infiltrating Lymphocyte Therapy Incorporating CD8 PET Imaging
Conditions
Lung Cancer, Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
Intervention / Treatment
- Drug: Zirconium Zr 89 crefmirlimab berdoxam
- Diagnostic Test: PET/CT Scan
Other Study ID Numbers
- 24-369
Start Date (Actual)
2025-03-03
Primary Completion Date (Actual)
2026-08-24
Study Completion Date (Actual)
2026-08-24
Enrollment (Actual)
4
Study Type
Interventional
Phase
Phase 1